Man Group
NPCE icon

Man Group’s Neuropace NPCE Stock Holding History

Man Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$577K Buy
43,897
+22,271
+103% +$334K ﹤0.01% 2032
2025
Q4 		$334K Buy
21,626
+1,920
+10% +$25.7K ﹤0.01% 1995
2025
Q3 		$203K Buy
+19,706
New +$186K ﹤0.01% 2103
2024
Q3 		– Sell
-38,470
Closed -$291K – 2125
2024
Q2 		$291K Buy
38,470
+528
+1% +$5.33K ﹤0.01% 1791
2024
Q1 		$501K Buy
37,942
+18,644
+97% +$266K ﹤0.01% 1777
2023
Q4 		$199K Buy
+19,298
New +$154K ﹤0.01% 1920

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Man Group's NPCE Position: Q1 2026 in Review

Man Group increased its Neuropace (NPCE) stake by 103% in Q1 2026, buying an estimated $334K and bringing the position to 43,897 shares worth $577K. The position accounts for ﹤0.01% of the portfolio, ranked #2032.

Man Group first reported a position in NPCE in Q4 2023 and has held it in 6 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Man Group held 43,897 shares of Neuropace worth $577K as of Q1 2026.
  • Man Group bought 22,271 Neuropace shares in Q1 2026, an estimated $334K.
  • Neuropace made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2032 holding.
  • Man Group first reported a position in Neuropace in Q4 2023 and has held it in 6 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.